ArticleAlzheimer's & dementia (Amsterdam, Netherlands)2021
Subtle cognitive impairment as a marker of Alzheimer's pathologies and clinical progression in cognitively normal individuals.
Article in Alzheimer's & dementia (Amsterdam, Netherlands), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Exploring easily accessible neurophysiological biomarkers for predicting Alzheimer's disease progression: a systematic review.Alzheimer's research & therapy · 2024Pooled it
- Are cognitive subtleties too subtle to see? A diffusion tensor imaging validation of the subtle cognitive impairment test and other psychometric assessments in a normative sample.Brain imaging and behavior · 2026Article
- A unified model for staging amyloid and tau pathology in Alzheimer's disease.medRxiv : the preprint server for health sciences · 2026Article
- Validating the Amyloid Cascade Through the Revised Criteria of Alzheimer's Association Workgroup 2024 for Alzheimer Disease.Neurology · 2025Article
- The Alzheimer's Disease Neuroimaging Initiative in the era of Alzheimer's disease treatment: A review of ADNI studies from 2021 to 2022.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Review
- Relevance of Minor Neuropsychological Deficits in Patients With Subjective Cognitive Decline.Neurology · 2023Observational
- Association of Stages of Objective Memory Impairment With Incident Symptomatic Cognitive Impairment in Cognitively Normal Individuals.Neurology · 2023Article
- Memory markers in the continuum of the Alzheimer's clinical syndrome.Alzheimer's research & therapy · 2022Article
- Alzheimer's disease is an inherent, natural part of human brain aging: an integrated perspective.Free neuropathology · 2022Article
- Subtle cognitive impairment as a marker of Alzheimer's pathologies and clinical progression in cognitively normal individuals.Alzheimer's & dementia (Amsterdam, Netherlands) · 2021Article
- Rest-activity rhythm characteristics associated with lower cognitive performance and Alzheimer's disease biomarkers in midlife women.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
introductionSubtle cognitive impairment (SCI) may appear before pathological changes surpass thresholds for abnormality. We aimed to investigate whether SCI could predict Alzheimer's pathologies and advancement.
methodsA total of 816 cognitively normal individuals were enrolled to assess the longitudinal neuropathological and clinical correlates of baseline SCI, via linear mixed-effects and Cox proportional-hazard models. Cross-lagged panel models were used in specific time waves.
resultsSCI individuals had a faster increase in brain amyloid burden and a higher risk of conversion. They also showed greater rates of cerebrospinal fluid (CSF) phosphorylated tau (p-tau) DISCUSSION: Baseline SCI could be an imperative prediction indicator of clinical and pathological progression. It enables cognitive measures to be informative at a very early stage and provided objective criteria for high-risk population screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.